[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363718-105":59,"doc-detail-363718-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","artificial-intelligence-driven-integration-of-multibiofluid-omics-and-clinical-phenotype-enables-stratification-of-endometrial-cancer","Artificial intelligence-driven integration of multibiofluid omics and clinical phenotype enables stratification of endometrial cancer","","Li and colleagues develop an AI platform that integrates MALDI-TOF MS multi-biofluid omics with clinical data to stratify endometrial cancer. Multilevel modeling supports sensitive screening, accurate diagnosis, and detection of high-risk molecular subtypes. Using two independent cohorts from different clinical centers (531 for model development, 204 for external validation), the workflow fuses omics features with clinical factors to deliver robust decision support. A deployed web tool enables scalable translation for both resource-limited and personalized healthcare.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/artificial-intelligence-driven-integration-of-multibiofluid-omics-and-clinical-phenotype-enables-stratification-of-endometrial-cancer/363718/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/artificial-intelligence-driven-integration-of-multibiofluid-omics-and-clinical-phenotype-enables-stratification-of-endometrial-cancer/363718.png","ImageObject",300,407,{"name":92,"@type":93},"Bulrr","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the AI platform integrate to stratify endometrial cancer?","Question",{"text":112,"@type":113},"It integrates MALDI-TOF MS multi-biofluid omics with clinical data to enable endometrial cancer stratification.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the models validated and what cohorts were used?",{"text":117,"@type":113},"Two independent cohorts were used: 531 participants for model development and 204 participants for external validation from different clinical centers.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical tasks does the platform support after deployment as a web tool?",{"text":121,"@type":113},"The platform provides decision support for scalable screening, confirmation performance, and potential high-risk subtype detection.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363718,1790729907,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892115043,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nArtificial intelligence-driven integration of multibiofluid omics and clinical phenotype enables stratification of endometrial cancer  \nAuthors  \nDandan Li (李丹丹), Pengfei Wu (吴鹏飞), Jianxujie Zheng (郑健徐杰), ..., Chenqi Bai  \n(白陈祺), Xiaojun Chen (陈晓军), Liang Qiao (乔亮)  \nCorrespondence  \n[cxjlhjj@163.com](cxjlhjj@163.com) (X.C.),  \n[liang_qiao@fudan.edu.cn](liang_qiao@fudan.edu.cn) (L.Q.)  \nIn brief  \nLi et al. develop an AI platform integrating MALDI-TOF MS multi-biofluid omics and clinical data for endometrial cancer stratification. Multilevel models enable sensitive screening, accurate diagnosis, and high-risk subtype detection. Deployed as a web tool, the platform offers scalable decision support for both resource-limited and personalized healthcare settings.  \n• Integrating plasma-cervical multi-omics with clinical data enables EC screening  \n• Uterine secretion metabolomics aids EC diagnosis and highrisk subtype detection  \n• The 2M-EC web platform integrates multi-modal models for clinical translation  \nLi et al., 2026, Cell Reports Medicine 7, 102805  \nJune 16, 2026 © 2026 The Author(s) . Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2026.102805](https://doi.org/10.1016/j.xcrm.2026.102805)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nArtificial intelligence-driven integration of multi-biofluid omics and clinical phenotype enables stratification of endometrial cancer  \nDandan Li (李丹丹),1,3 Pengfei Wu (吴鹏飞),1,3 Jianxujie Zheng (郑健徐杰),1 YunhanYang (杨韵涵),1 Weiwei Shan (单伟伟),2 Jia Yi (易佳),1 Dan Zhao (赵丹),1 Shijun Yang (杨世俊),1 Yiwei Hu (胡一苇),1 Xinying Zhu (朱欣颖),1 Ruibin Fan (范瑞彬),1 Pengxiao Fu (付鹏霄),1 Chenqi Bai (白陈祺),1 Xiaojun Chen (陈晓军),1,2,* and Liang Qiao (乔亮)1,4,*  \n1Department of Chemistry, and Obstetrics and Gynecology Hospital of Fudan University, Fudan University, Shanghai 200433, China  \n2Shanghai Tenth People’s Hospital of Tongji University, Shanghai 200072, China  \n3These authors contributed equally  \n4Lead contact  \n*Correspondence: [cxjlhjj@163.com](cxjlhjj@163.com) (X.C.), [liang_qiao@fudan.edu.cn](liang_qiao@fudan.edu.cn) (L.Q.) [https://doi.org/10.1016/j.xcrm.2026.102805](https://doi.org/10.1016/j.xcrm.2026.102805)  \nSUMMARY  \nEndometrial cancer (EC) incidence is rising, yet current diagnostics lack precision and scalability. We develop an artificial intelligence (AI)-based platform integrating multi-biofluid omics and clinical data for EC stratification. Using two independent cohorts from different clinical centers (531 participants for model development, 204 for external validation), we collect 1,179 samples (plasma, cervical/uterine secretions) and the corresponding clinical data (age, ultrasound, etc.) . Machine learning identifies EC-specific signatures, and the AI framework fuses omics features with clinical factors to enable multilevel risk stratification. On the external validation cohort, the platform achieves 95.65% sensitivity for minimally invasive EC screening and balanced performance with an area under the curve (AUC) value of 0.94 for EC confirmation. The model also shows potential for high-risk subtype detection. Biological plausibility is supported by identified omics signatures. A web tool is developed to support clinical translation. This platform demonstrates the potential of multi-omicsand AI in precision oncology.  \nINTRODUCTION  \nEndometrial cancer (EC) is a prevalent gynecological malignancy, with its incidence rising due to socioeconomic development and population aging. According to Global Cancer Statistics 2022 , there were 420,242 new EC cases worldwide in 2022, with over 90% of the cases occurring in women over the age of 50.1 The current gold standard for diagnosing EC is endometrial biopsy or hysteroscopy-guided biopsy, which is highly invasive.2 The decision to proceed with tissue biopsy is guided by findings from initial screening of EC. The current initial screening of EC mainly relies on transvaginal ultrasound,3 which is primarily effective in postmenopausal wom","cbCaiuLOvGFHoQyT","https://ap.wps.com/l/cbCaiuLOvGFHoQyT","pdf",9910022,26,"English","# Summary\n## AI platform and data integration\n## Cohorts, validation, and performance\n## Clinical translation via web tool","[{\"question\":\"What does the AI platform integrate to stratify endometrial cancer?\",\"answer\":\"It integrates MALDI-TOF MS multi-biofluid omics with clinical data to enable endometrial cancer stratification.\"},{\"question\":\"How were the models validated and what cohorts were used?\",\"answer\":\"Two independent cohorts were used: 531 participants for model development and 204 participants for external validation from different clinical centers.\"},{\"question\":\"What clinical tasks does the platform support after deployment as a web tool?\",\"answer\":\"The platform provides decision support for scalable screening, confirmation performance, and potential high-risk subtype detection.\"}]","Artificial intelligence-driven integration of multibiofluid omics and clinical phenotype enables stratification of endometrial cancer | PDF",1790152796,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/388d19dcabb1d263b402be010e35ed7b.webp",983,1276,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7900ac24809909de7249f6667ef5447.webp",982,1275,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7deef284faa4da7a760ef476fd119d60.webp",981,1273,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b762154377166568b2e16a006126b8d7.webp",980,1272]